Aclaris Therapeutics (ACRS) Prices 4M Stock Offering at $22.75/Share
- Wall Street dips as investors ready for Trump's inauguration
- Western Union (WU) Admits Anti-Money Laundering and Consumer Fraud Violations, Forfeits $586M in Settlement
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- Apple (AAPL) PT Raised to $140 at BofA/Merrill Lynch; iPhone 8 Will be 'Super-Long' Cycle
- Morgan Stanley Upgrades Tesla Motors (TSLA) to Overweight
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $22.75 per share. The gross proceeds from the offering to Aclaris are expected to be $91.0 million. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the public offering price, less the underwriting discount. The net proceeds from the offering to Aclaris are expected to be $85.2 million, after deducting underwriting discounts and commissions and estimated offering expenses, but excluding any exercise of the underwriters’ option. The offering is expected to close on or about November 23, 2016, subject to customary closing conditions.
Jefferies LLC, Leerink Partners LLC and Guggenheim Securities LLC are acting as joint book-running managers for the offering. William Blair & Company, L.L.C. is acting as lead manager for the offering and JMP Securities LLC is acting as co-manager.
Aclaris intends to use the net proceeds from the offering to fund the submissions for regulatory approval of its drug candidate A-101 Topical Solution (A-101) for the treatment of seborrheic keratosis (SK), to develop a commercial sales force to market A-101 for the treatment of SK, if approved, to fund the continued research and development of A-101 for the treatment of common warts and its JAK inhibitor drug candidates ATI-50001 and ATI-50002 for the treatment of alopecia areata, to fund preclinical development and formulation of a JAK inhibitor drug candidate for the treatment of androgenetic alopecia and vitiligo, and for working capital and general corporate purposes.
A shelf registration statement relating to this offering was filed with the Securities and Exchange Commission (SEC) on November 2, 2016 and declared effective by the SEC on November 14, 2016. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at Prospectus_Department@Jefferies.com, or by phone at (877) 547-6340; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: (800) 808-7525, ext. 6142, email: syndicate@Leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at 212-518-9658, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bill Barrett Corporation (BBG) Entered Confidentiality Agreement with Bonanza Creek Energy (BCEI) Pertaining to BCEI's Chapter 11 Proceeding
- UniPixel (UNXL) Reports MOU for Strategic Partnership with General Interface Solution
- Evans Bancorp (EVBN) Prices 400K Offering of Common Stock
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesWilliam Blair, Jefferies & Co, JMP Securities, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!